Shop by goal
Popular compounds
Research resources
Recently viewed
Peptide Compound Profiles
Individual research compounds explained step by step - what the molecule is, what study contexts it appears in, and how researchers frame it.
60 articles tagged “Compound Profiles”
5-Amino-1MQ: NNMT-Inhibitor Research Guide (Fat Loss & NAD+ Longevity)
Not actually a peptide - a small-molecule NNMT inhibitor studied for fat-cell metabolism, NAD+ and SAM preservation, and grip strength in obesity models. The mechanism, the entirely-preclinical evidence base (Neelakantan 2022, Babula 2024), the pharmacokinetics, storage, and how it differs from a peptide like MOTS-C. Research use only.
Selank: Anxiolytic Nootropic Peptide Research Guide
A tuftsin-derived heptapeptide (TKPRPGP) studied as a non-sedating anxiolytic - GABAergic modulation, BDNF elevation, and the Russian clinical study that compared it with the benzodiazepine medazepam. Mechanism, evidence, Selank vs Semax, and honest framing. Not FDA-approved; research use only.
Hexarelin vs CJC-1295: GHSR/CD36 Potency vs GHRH-R Signalling
Hexarelin and CJC-1295 are two ends of the same GH axis - the ghrelin-receptor/CD36 arm against the GHRH-receptor arm. Mechanism, half-life, desensitisation, DAC vs no-DAC, and why the literature co-studies them rather than ranking them. Research use only.
Best Peptides for Muscle Growth Research (2026): The Compounds Labs Actually Study
The peptides that dominate muscle-growth research - IGF-1 LR3, MGF/PEG-MGF, the GH-axis secretagogues (hexarelin, ipamorelin, CJC-1295, GHRP-2/6, sermorelin, tesamorelin) and the recovery pair BPC-157 + TB-500. Mechanism by mechanism, honest about the human-trial gap and the WADA reality. Research use only.
Best Peptides for Testosterone Research (2026): The HPG-Axis Compounds, Explained
Peptides do not boost testosterone the way TRT does - they are studied on the HPG axis. The two research compounds that actually intersect it (kisspeptin upstream, HCG at the testis), why GH-axis peptides do not raise testosterone, and the honest research framing. Research use only; not a TRT substitute.
Peptides and Menopause Research (2026): What the Literature Actually Studies
An honest research-landscape map: there is no menopause treatment peptide, and menopause is a clinical matter for a doctor. Which research compounds appear in the broader midlife and hormonal-change research conversation - metabolic, skin/collagen, reproductive-axis - and where the evidence stops. Research use only; not medical advice.
TB-500 in sport: banned without a performance claim, and how labs detect it
TB-500 is prohibited at all times in tested sport even though its reputation is recovery, not raw performance. Why a recovery peptide is banned under WADA S2.3, and the metabolism science anti-doping labs use to catch it.
TB-500 in equine recovery research: what the science actually studies
Why the horse is a serious soft-tissue-repair model, the real actin/cell-migration mechanisms behind TB-500, the human-to-horse evidence gap, and the racing anti-doping reality most sellers omit.
BPC-157 in equine soft-tissue research: mechanism, evidence & the racing reality
The real angiogenic and fibroblast-migration mechanisms behind BPC-157’s equine "soft-tissue" claims, why the evidence is overwhelmingly preclinical, the human-to-horse gap, and the medication-control rules recovery marketing skips.
Why Reta Searches Are Surging in the USA: A 2026 Search-Trend Report
US search interest in retatrutide ("reta", LY3437943) has gone from near-zero to a Google Trends Breakout term since 2023. What is driving the surge, what the data does and does not mean, and how US researchers source it. Search-interest data only - research use only.
Retatrutide Search Demand in the UK: The 2026 Surge, Explained
UK search interest in retatrutide ("reta") has climbed from near-zero to a Google Trends Breakout term since 2023. What is driving the UK surge, the MHRA framing, and how UK researchers source it. Search-interest data only - research use only.
Tirzepatide (Tirz) Search Demand in the USA: A 2026 Trend Report
US search interest in tirzepatide ("tirz", Mounjaro, Zepbound) climbed steeply from 2022. The search arc, why an FDA-approved drug also drives research-compound interest, and the framing that matters. Search-interest data only - research use only.
Beyond GLP-1: Amylin, Glucagon, GIP and the Next Obesity Research Wave
Obesity research has moved past GLP-1 alone. This hub maps the next-generation mechanisms - GIP agonism and antagonism, glucagon, and amylin - and the candidate landscape from tirzepatide and retatrutide to MariTide, CagriSema, survodutide, amycretin and petrelintide. Research use only.
Orforglipron: a research guide to the first oral non-peptide GLP-1
Eli Lilly's once-daily oral small-molecule GLP-1 receptor agonist - not a peptide. Mechanism, the ATTAIN Phase 3 data (~12.4% at 72 weeks), why a pill changes access, and how it differs from the research peptides. Research use only.
MariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1/GIP Research Profile
Amgen's once-monthly peptide-antibody conjugate pairs GLP-1 agonism with GIP antagonism - the unusual mechanism, the Phase 2 data (up to ~20%), and where it sits in the obesity pipeline. Research use only.
CagriSema & Cagrilintide: The Amylin + GLP-1 Combo Explained
Novo Nordisk's combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 agonist) - the mechanism, the REDEFINE Phase 3 data (~20-23%), and why amylin is the next obesity-research mechanism. Research use only.
Amycretin: Novo Nordisk's GLP-1 and Amylin Candidate Explained
Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist in oral and injectable development - the science, the early data (~22% injectable at 36 weeks), and how it compares to CagriSema. Research use only.
Survodutide: GLP-1, Glucagon and the MASH Opportunity
Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist studied for obesity and MASH - the mechanism, the SYNCHRONIZE program, the ~16.6% Phase 3 weight loss, and the distinctive liver-fat angle. Research use only.
Petrelintide: Zealand and Roche's Amylin Analogue Explained
Zealand Pharma and Roche's investigational long-acting amylin analogue - the amylin-first obesity strategy, the Phase 2 data (~10.7% at week 42), and why an amylin-only approach matters. Research use only.
Is Retatrutide Safe? What the Research and the Safety Warnings Actually Show
After 2026 news reports of retatrutide ("reta") being sold online despite its unapproved status, what the research actually shows on safety: the Phase 2 adverse-event picture (dose-dependent GI effects, a heart-rate signal), the long-term unknowns, why self-sourcing is the real risk, and the research-use-only line.
Retatrutide Phase 3: The Triple-Hormone GLP-1 Story
Retatrutide Phase 3 data was presented at the 2026 ADA Sessions. Here is a research-focused look at why triple-hormone agonists now lead the GLP-1 conversation.
Monthly GLP-1 Research: Berobenatide and the Next Wave
Pfizer presented berobenatide data on monthly GLP-1 dosing. Here is what long-acting metabolic research signals about adherence, tolerability and the pipeline.
Beyond Weight Loss: The Next GLP-1 Battle
The next phase of GLP-1 research is about tolerability, muscle preservation and long-term adherence, not just headline weight-loss percentages. A mature overview.
July 2026 FDA Peptide Meeting: What to Know
The FDA's July 23-24, 2026 compounding committee will discuss BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. A clear, neutral regulatory explainer.
GHK-Cu for Hair Loss: Research Mechanism, Dosing, Results Timeline
GHK-Cu copper peptide for hair loss: mechanism (collagen remodeling, DHT modulation, angiogenesis), pre-clinical evidence, dosing protocols, application methods, and research on hair follicle recovery.
Peptide Side Effects Comparison: BPC-157, TB-500, GHK-Cu, MOTS-c
Comprehensive peptide side effects comparison chart: BPC-157, TB-500, GHK-Cu, MOTS-c, ipamorelin. Pre-clinical safety data, injection site effects, systemic toxicity, and human evidence gaps.
Shoulder Injury Recovery with Peptides: BPC-157, TB-500 Research
Peptide protocols for shoulder injury recovery: BPC-157 and TB-500 for rotator cuff, ACL, tendon damage. Pre-clinical research, dosing, injection protocols, and recovery timeline.
BPC-157: what the research actually says
A research-first breakdown of the body protection compound - what BPC-157 is, the preclinical-only evidence base, the peptide-vs-steroid question, why recovery and hormonal claims overreach, and why purity and COAs matter.
Tesamorelin: what it is and what the research shows
The GHRH analogue mechanism, the narrow approved visceral-fat indication, how tesamorelin differs from recovery peptides, and where general fat-loss and longevity claims go too far.
TB-500 and Thymosin Beta-4: a research overview
How TB-500 relates to (but differs from) Thymosin Beta-4, what the preclinical tissue-repair and cell-migration literature actually studies, the human-trial gap, and why it is prohibited in tested sport.
PT-141 (Bremelanotide): a research guide to the melanocortin agonist for sexual arousal
PT-141 is an FDA-approved melanocortin-4 receptor agonist for hypoactive sexual desire disorder. How it works, clinical evidence from the DESIRE trials, nasal spray vs injection, comparison to Viagra/Cialis, dosage, side effects, and why the mechanism differs from phosphodiesterase inhibitors.
FDA peptide review 2026: what the July meeting could mean for BPC-157, TB-500, Semax and Epitalon
The FDA's Pharmacy Compounding Advisory Committee reviews BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon on July 23-24, 2026 for potential 503A Bulks List inclusion. What the meeting means for research, regulation and accessibility - and why a compounding review is not an FDA approval.
BPC-157 and TB-500 under FDA review: why regenerative peptide research is entering a new era
BPC-157 and TB-500 are scheduled for FDA advisory committee discussion on July 23, 2026 (evaluated uses: ulcerative colitis and wound healing). What it means for regenerative peptide research, compounding policy and research-use standards - and why a review is not an approval.
Semax, Epitalon and DSIP: why neuro-longevity peptides are part of the FDA's 2026 review
On July 24, 2026 the FDA's compounding advisory committee discusses Semax, Epitalon and Emideltide (DSIP). What it could mean for neuro-longevity peptide research and compounding regulation - and why a review is not an approval or a clinical endorsement.
Is BPC-157 FDA approved? The 2026 regulatory status, explained
No - BPC-157 is not an FDA-approved drug. It has never completed a New Drug Application and is supplied as a research-use-only compound. The 2026 status, including the July 2026 503A compounding review, and why a review is not an approval.
Is BPC-157 banned? What the FDA has and hasn't done
Not in the way the word suggests. BPC-157 is a research-use-only compound; the FDA's 2023 review kept it off the 503A Bulks List for human-use compounding, it returns for discussion in July 2026, and WADA prohibits it in sport. The nuance behind "banned", explained.
KPV peptide and the FDA: what the July 2026 review means
KPV - the anti-inflammatory tripeptide (lysine-proline-valine) derived from alpha-MSH - is on the FDA's July 23, 2026 compounding agenda (evaluated uses: wound healing and inflammatory conditions). What KPV is, the research context, and why a review is not an approval.
Is TB-500 FDA approved? The 2026 regulatory status, explained
No - TB-500 is not an FDA-approved drug. It is a research-use-only peptide related to thymosin beta-4. The 2026 status, the July 2026 503A compounding review, the WADA sport ban, and why a review is not an approval.
Is Semax FDA approved? The 2026 regulatory status, explained
No - Semax is not FDA approved in the US (though it is a registered medicine in Russia). It is supplied as a research-use-only compound. The 2026 status, the July 2026 503A review, and why a review is not an approval.
Is Epitalon FDA approved? The 2026 regulatory status, explained
No - Epitalon (also spelled Epithalon) is not an FDA-approved drug; it is a research-use-only compound studied in longevity research. The 2026 status, the July 2026 503A review, and why a review is not an approval.
FDA moves to end mass-compounded GLP-1s: what the 503B proposal means
In April 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would end large-scale compounding of these GLP-1 drugs. The proposal, the June 2026 comment deadline, and how it differs from the research-compound space.
FDA peptide reclassification 2026: what changed, and why
How peptides went from FDA Category 2 prohibition in 2023 to a fresh 503A review in 2026 - the April 2026 Federal Register notice, the 12 peptides under review, the compounder lawsuits, the HHS policy push, and what the July 2026 PCAC meeting will decide.
Scientists map 9 peptides for healthy aging: a 2026 peer-reviewed review
A 2026 review in Frontiers in Aging maps nine therapeutic peptides onto the hallmarks of aging - from tirzepatide and Epitalon to GHK-Cu, BPC-157, TB-500, Semax, CJC-1295/Ipamorelin and PT-141 - separating FDA-approved agents from investigational compounds.
Peptides and Stem Cells: how they work together in regenerative medicine research
How peptides intersect with stem-cell and regenerative-medicine research - as signalling molecules, as self-assembling hydrogel scaffolds for 3D cell culture, and as growth factors such as IGF-1. What the peer-reviewed literature describes vs the longevity-clinic claims. Research use only.
IGF-1 DES vs IGF-1 LR3: a research guide to the two modified IGF-1 analogues
Des(1-3) IGF-1 vs Long R3 IGF-1 compared - structure, IGF-binding-protein affinity, half-life and potency, the recombinant-protein research context, and the WADA/USADA prohibited status with health-risk warnings. Research use only; not for human use.
Ipamorelin vs Sermorelin: two routes to the same GH pulse
Ipamorelin is a selective ghrelin-receptor (GHSR) agonist; sermorelin is a GHRH analogue acting upstream on the pituitary. Mechanism, GH-release shape, side-effect comparison, and why the two are co-studied as a complementary pair. Research use only.
Hexarelin vs Ipamorelin: potency against selectivity
Both are ghrelin-receptor (GHSR) agonists, but hexarelin is the more potent GH releaser with CD36 cardiac activity, while ipamorelin is the cleaner, selective option with slower desensitisation. Mechanism, side effects and desensitisation compared. Research use only.
Tesamorelin vs Sermorelin: two GHRH analogues compared
Both prompt the pituitary through the GHRH receptor, but tesamorelin is a stabilised, more potent molecule with dedicated visceral-fat research, while sermorelin is the shorter GHRH 1-29 fragment. Mechanism, potency and half-life compared. Research use only.
Tirzepatide: a research guide to the dual GLP-1 / GIP agonist
A 39-amino-acid dual agonist developed by Eli Lilly, approved as Mounjaro and Zepbound. Mechanism, half-life, the SURPASS and SURMOUNT trial data, the SURMOUNT-5 head-to-head against semaglutide, and the Tirzepatide research-compound posture.
Semaglutide: a research guide to the GLP-1 single agonist
The 31-amino-acid peptide behind Ozempic, Wegovy and Rybelsus. Mechanism, half-life, the STEP / SUSTAIN / SELECT evidence base, oral vs injectable formulation, and the Semaglutide research-compound posture.
Retatrutide: a research guide to the triple GLP-1 / GIP / glucagon agonist
Eli Lilly’s investigational triple agonist (LY3437943). Mechanism, the ~24% Phase 2 weight-reduction headline, the TRIUMPH Phase 3 programme, and the Retatrutide research-compound posture. Pairs with the UK sourcing guide.
BPC-157: a research guide to the body protective compound
The 15-amino-acid pentadecapeptide derived from a body protective compound first isolated in human gastric juice. Mechanism (angiogenesis, NO modulation, fibroblast migration), the pre-clinical evidence base, the human-trial gap, and the “Wolverine stack” framing with TB-500.
Tesamorelin: a research guide to the GHRH analogue
The only FDA-approved peptide for visceral fat reduction. A 44-amino-acid GHRH analogue with a trans-3-hexenoic acid N-terminal modification - mechanism, the NEJM Phase 3 visceral-adipose-tissue data, and how it differs mechanistically from CJC-1295 and sermorelin.
CJC-1295 & ipamorelin: a research guide to the GHRH + GHRP pair
The most-studied GHRH + GHRP research combination. CJC-1295 with DAC vs no-DAC explained, ipamorelin’s selective ghrelin-receptor mechanism, why the pairing has mechanistic logic rather than just marketing logic, and how the pair compares to tesamorelin and sermorelin.
Peptides & bodybuilding: a research map of the compounds in the conversation
A neutral research-side map of the peptides that come up in bodybuilding discussion - GH-axis stack, healing pair (BPC-157 + TB-500), GLP-1 cluster for cuts. WADA framing throughout.
TB-500 & golf recovery: a research look at the game’s soft-tissue toll
Golf injuries are asymmetric, rotational and chronic. Why TB-500 keeps coming up in tour-locker-room conversation - mechanism, the human-trial gap, and the WADA listing every competitor needs to know.
BPC-157 & tattoo healing: what the research says about recovery
A tattoo is, biologically, a controlled dermal injury. The four wound-healing phases, BPC-157’s animal-study mechanisms (angiogenesis, collagen organisation, fibroblast migration) and where the "Wolverine stack" with TB-500 fits in.
GHK-Cu (copper peptide) in plain English
Why labs care about this tiny copper-bound peptide: skin matrix, gene-expression studies and wound models - explained step by step for non-specialists.
MOTS-c: what “mitochondrial peptide” means
A short signal from the cell’s energy factories - how researchers link it to exercise, metabolism and ageing models, without hype.
Semaglutide vs Tirzepatide, simply put
Two heavily studied metabolic peptides side by side: how they are alike, how they differ, and what papers usually measure - without treating either as a consumer product.
Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.
Browse the full catalogue
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io